Improving Metabolic Parameters of Antipsychotic Child Treatment.

Trial Profile

Improving Metabolic Parameters of Antipsychotic Child Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Aripiprazole (Primary) ; Metformin (Primary) ; Perphenazine (Primary) ; Asenapine; Iloperidone; Lurasidone; Olanzapine; Quetiapine; Risperidone; Ziprasidone
  • Indications Bipolar disorders; Metabolic disorders; Psychotic disorders; Weight gain
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Planned number of patients changed from 240 to 132 as reported by ClinicalTrials.gov.
    • 20 Apr 2012 Investigational drugs (ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, perphenazine) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top